Sign up Australia
Proactive Investors - Run By Investors For Investors

GI Dynamics, Inc reveals positive data for obesity treatment device

Patients receiving the treatment achieved 10% decrease in BMI.
GI Dynamics, Inc reveals positive data for obesity treatment device
Obesity has a significant effect on morbidity for adolescents

GI Dynamics, Inc (ASX:GID) has completed the enrolment and received positive preliminary results in the first clinical trial evaluating its EndoBarrier device for obese adolescents.

The company’ share price has doubled since the start of 2017, last trading at $0.046.

EndoBarrier is an endoscopically delivered device therapy for the treatment of type 2 diabetes and obesity.

GI Dynamics conducted the study at the University Children’s Hospital (UCH) in Ljubljana, Slovenia.

The study was designed to determine the efficacy and safety of the EndoBarrier treatment for up to one year in morbidly obese adolescents.

Preliminary data show that patients who received the treatment saw an average of 10% decrease in body mass index (BMI) and metabolic improvements.

EndoBarrier demonstrated therapeutic benefit in treating prediabetes, as blood sugar levels were reduced by 6%.

Most notable was the 49% improvement in HOMA-IR (Homeostatic Model Assessment), a critical measure of insulin resistance and beta-cell function.

EndoBarrier demonstrated an acceptable safety profile, with all study subjects completing treatment to the intended twelve-month implant duration.

Obesity and its complications have a significant effect on morbidity and mortality for adolescents.

Standard treatment-based diets and cognitive therapy have limited effects. Surgical bariatric procedures are non-reversible and permanently alter certain metabolic functions.

EndoBarrier is less invasive than surgery and can be inserted in a quick outpatient endoscopic procedure that patients are likely to find more acceptable.

GI Dynamics is well funded with a cash balance of $8.3 million as at 31 December 2016.

Register here to be notified of future . Company articles
View full . profile View Profile

Proactive Investors Australia Timeline

Related Articles

February 21 2017
One particular development of note is Cello Pulsar, a social media analytics tool that has, according to the experts, the potential to be a real winner.
Laptop screen with graphs
August 04 2017
Total revenues for the six months to 30 June grew by 5%, with Ebiquity adding it remains confident in hitting its operating profits and earnings targets for the rest of the year
learning symbol on a keyboard
January 17 2017
The English language learning specialist is confident it can kick on in the coming year

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use